Retrospective data analysis of a German cohort of patients with active relapsing multiple sclerosis switching from anti-CD20 therapies to cladribine tablets and vice versa

被引：0
|
作者：
Konen, Franz Felix [1 ]
Pfeuffer, Steffen [2 ]
Jendretzky, Konstantin Fritz [1 ]
Gehring, Klaus [3 ]
Elias-Hamp, Birte
Suehs, Kurt-Wolfram [1 ]
Pawlitzki, Marc [4 ]
Meuth, Sven [4 ]
Kleinschnitz, Christoph [5 ,6 ]
Pul, Refik [5 ,6 ]
Skripuletz, Thomas [1 ]
机构：
[1] Hannover Med Sch, Dept Neurol, Hannover, Germany
[2] Justus Liebig Univ Giessen, Univ Hosp Giessen & Marburg, Dept Neurol, Giessen, Germany
[3] Neurozentrum Klosterforst, Itzehoe, Germany
[4] Heinrich Heine Univ Duesseldorf, Univ Hosp Duesseldorf, Dept Neurol, Dusseldorf, Germany
[5] Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, Essen, Germany
[6] Ctr Translat Neuro & Behav Sci C TNBS, Essen, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P293/939
引用
收藏
页码：328 / 330
页数：3
相关论文
共 50 条
  • [11] Leptomeningeal enhancement under anti-CD20 therapies - a monocentric retrospective cohort study of 70 patients
    Friedli, C.
    Wagner, F.
    Diem, L.
    Salmen, A.
    Chan, A.
    Hoepner, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 142 - 142
  • [12] Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
    Januel, Edouard
    Hajage, David
    Labauge, Pierre
    Maillart, Elisabeth
    De Seze, Jerome
    Zephir, Helene
    Pelletier, Jean
    Guilloton, Laurent
    Bensa, Caroline
    Heinzlef, Olivier
    Casez, Olivier
    Biotti, Damien
    Bourre, Bertrand
    Vukusic, Sandra
    Maurousset, Aude
    Berger, Eric
    Laplaud, David
    Lebrun-Frenay, Christine
    Dubessy, Anne-Laure
    Branger, Pierre
    Thouvenot, Eric
    Clavelou, Pierre
    Sellal, Francois
    Manchon, Eric
    Moreau, Thibault
    Papeix, Caroline
    Tubach, Florence
    Louapre, Celine
    JAMA NETWORK OPEN, 2023, 6 (06) : E2319766
  • [13] Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 vaccine in a cohort of patients with multiple sclerosis
    Correa-Diaz, E. P.
    Barrera Madera, R.
    Torres Herran, G.
    Jacome Sanchez, C.
    Gualotuna Pachacama, W.
    Llerena Pallango, A.
    Piedra Andrade, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 838 - 838
  • [14] Anti-CD20 and natalizumab in highly active relapsing-remitting multiple sclerosis: the SWIFNA-20 comparative effectiveness study
    Laplaud, D. -A.
    Rollot, F.
    Casey, R.
    Wiertlewski, S.
    Pelletier, J.
    De Seze, J.
    Labauge, P.
    Ruet, A.
    Thouvenot, E.
    Ciron, J.
    Clavelou, P.
    Stankoff, B.
    Bourre, B.
    Lebrun-Frenay, C.
    Maillart, E.
    Defer, G.
    Camdessanche, J. -P.
    Maurousset, A.
    Hankiewicz, K.
    Bakchine, S.
    Montcuquet, A.
    Vukusic, S.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 678 - 680
  • [15] Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
    Jeantin, Lina
    Abdi, Basma
    Soulie, Cathia
    Sterlin, Delphine
    Maillart, Elisabeth
    Beigneux, Ysoline
    Hippolyte, Amandine
    Belin, Lisa
    Marcelin, Anne-Genevieve
    Pourcher, Valerie
    Louapre, Celine
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (01): : 19 - 28
  • [16] Comparison of anti-CD20 therapies versus other disease modifying therapies on postpartum disease activity in patients with multiple sclerosis
    Passeri, M.
    Alvarez, E.
    Shah, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 462 - 462
  • [17] EFFICACY OF CLADRIBINE TABLETS IN PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS: ANALYSIS OF POOLED DOUBLE-BLIND DATA FROM THE CLARITY AND ONWARD STUDIES
    Giovannoni, Gavin
    Montalban, Xavier
    Rammohan, Kottil
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Dangond, Fernando
    King, John
    Damian, Doris
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E27 - E28
  • [18] Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
    Fabien Rollot
    Justine Couturier
    Romain Casey
    Sandrine Wiertlewski
    Marc Debouverie
    Jean Pelletier
    Jérôme De Sèze
    Pierre Labauge
    Aurélie Ruet
    Eric Thouvenot
    Jonathan Ciron
    Eric Berger
    Olivier Gout
    Pierre Clavelou
    Bruno Stankoff
    Olivier Casez
    Bertrand Bourre
    Hélène Zephir
    Thibault Moreau
    Christine Lebrun-Frenay
    Elisabeth Maillart
    Gilles Edan
    Jean-Philippe Neau
    Alexis Montcuquet
    Philippe Cabre
    Jean-Philippe Camdessanché
    Gilles Defer
    Haifa Ben Nasr
    Aude Maurousset
    Karolina Hankiewicz
    Corinne Pottier
    Emmanuelle Leray
    Sandra Vukusic
    David-Axel Laplaud
    Neurotherapeutics, 2022, 19 : 476 - 490
  • [19] Efficacy of cladribine tablets 3.5 mg/kg in patients with highly active relapsing multiple sclerosis (RMS): Pooled analysis of the double-blind cohort from CLARITY and ONWARD
    Giovannoni, G.
    Montalban, X.
    Damian, D.
    Dangond, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 332 - 332
  • [20] OLIKOS Study: 6-Month Interim Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies
    Hua, Le
    Brown, Brandon
    Camacho, Elizabeth
    Greenberg, Benjamin M.
    Henry, Roland
    Piccolo, Rebecca
    Alvarez, Enrique
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1101 - 1102
12345